Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme
glucocerebrosidase (GCB). Due to the deficiency of functional GCB, glucocerebroside
accumulates within macrophages leading to cellular engorgement, organomegaly, and organ
system dysfunction. The purpose of this non-inferiority study is to evaluate the efficacy
and safety of GA-GCB (velaglucerase alfa) administered every other week in comparison to
imiglucerase in treatment naive patients with type 1 Gaucher disease.
Type 1 Gaucher disease, the most common form, accounts for more than 90% of all cases and
does not involve the CNS. Typical manifestations of type 1 Gaucher disease include
hepatomegaly, splenomegaly, thrombocytopenia, bleeding tendencies, anemia, hypermetabolism,
skeletal pathology, growth retardation, pulmonary disease, and decreased quality of life.
Gene-Activated® human glucocerebrosidase (GA-GCB; velaglucerase alfa) is produced in a
continuous human cell line using proprietary gene-activation technology and has an identical
amino acid sequence to the naturally occurring human enzyme. GA-GCB (velaglucerase alfa)
contains terminal mannose residues that target the enzyme to the macrophages-the primary
target cells in Gaucher disease. This study was designed to determine the efficacy and
safety of GA-GCB (velaglucerase alfa) in comparison to imiglucerase in men, women, and
children with Type 1 Gaucher disease.
- The patient has a documented diagnosis and clinical manifestation of type 1 Gaucher
- The patient is at least 2 years of age.
- The patient has not received treatment for Gaucher disease (investigational products,
miglustat, or imiglucerase) within 12 months prior to study entry, as documented in
the patient's medical history.
- Female patients of child-bearing potential must agree to use a medically acceptable
method of contraception at all times during the study and must have negative results
to a pregnancy test performed at the time of enrollment and as required throughout
their participation in the study. Male patients must use a medically acceptable
method of birth control throughout their participation in the study and must report
their partner's pregnancy.
- The patient, the patient's parent(s) or legal guardian(s) has provided written
informed consent that has been approved by the Institutional Review Board/Independent
Ethics Committee (IRB/IEC).
- The patient must be sufficiently cooperative to participate in this clinical study as
judged by the Investigator.
- The patient has type 2 or 3 Gaucher disease or is suspected of having type 3 Gaucher
- The patient has received treatment with any non-Gaucher disease-related
investigational drug or device within the 30 days prior to study entry; such use
during the study is not permitted.
- The patient is known to be positive for human immunodeficiency virus (HIV).
- The patient is known to be positive for hepatitis B and/or C.
- The patient, patient's parent(s), or patient's legal guardian(s) is/are unable to
understand the nature, scope, and possible consequences of the study.
- The patient has a significant comorbidity(ies) that might affect study data or
confound the study results (e.g., malignancies, primary biliary cirrhosis, autoimmune
liver disease, etc.).
- The patient is unable to comply with the protocol, e.g., has a clinically relevant
medical condition making implementation of the protocol difficult, has an
uncooperative attitude, is unable to return for safety evaluations, or is otherwise
unlikely to complete the study, as determined by the Investigator.